

Pfizer Satellite Symposium at the 18th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) 2025

A new era of haemophilia care with marstacimab

 5th February 2025

 15:30–16:45

 Milan, Italy

Symposium objectives

This symposium aims to illustrate some of the key practical considerations for patient management in the new era of haemophilia therapy. We will discuss clinical decision making, choosing the appropriate type of treatment within an evolving treatment landscape, understanding efficacy and safety, and associated informational needs.

Speakers



Víctor Jiménez-Yuste

Head of the Haematology Department,
Hospital Universitario La Paz,
Madrid, Spain



Davide Matino

Associate Professor of Medicine (Division of
Haematology and Thromboembolism),
McMaster University, Hamilton, ON, Canada

Agenda

| Time | Title | Presenter |
|------------------|---|--|
| 15:30 5 mins | Welcome and introduction Navigating the treatment landscape in a new era of care | Chair: Víctor Jiménez-Yuste (Spain) |
| 15:35 60 mins | Clinical considerations for practical implementation of marstacimab and other approved novel rebalancing therapies | Davide Matino (Canada) Víctor Jiménez-Yuste (Spain) |
| 16:35 10 mins | Q&A | Moderator: Víctor Jiménez-Yuste (Spain) |
| 16:45 | Close | |

Marstacimab is authorised by EMA but is not commercialised in Italy.

This symposium has been organised and funded by Pfizer and is intended for healthcare professionals only.
PP-HYM-ITA-0001 © 2024 Pfizer Inc. All rights reserved. December 2024.

